Truist Financial
FDMT icon

Truist Financial’s 4D Molecular Therapeutics FDMT Stock Holding History

Truist Financial’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$333K Hold
25,000
– – ﹤0.01% 2473
2026
Q1 		$233K Hold
25,000
– – ﹤0.01% 2559
2025
Q4 		$188K Buy
+25,000
New +$254K ﹤0.01% 2624

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Truist Financial's FDMT Position: Q2 2026 in Review

Truist Financial held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 25,000 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #2473.

Truist Financial first reported a position in FDMT in Q4 2025 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Truist Financial held 25,000 shares of 4D Molecular Therapeutics worth $333K as of Q2 2026.
  • Truist Financial left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2473 holding.
  • Truist Financial first reported a position in 4D Molecular Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.